Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

AJMC

Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

By Brigham Walker, PhD
Lalan Wilfong, MD

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

August 31st 2015

Gene Signature Could Predict Development of Pancreatic Cancer, Allow Personalized Treatment

Surabhi Dangi-Garimella, PhD

A novel microRNA gene signature could guide earlier intervention in pancreatic cancer.

August 31st 2015

ASCO Updates Guidelines for Advanced Lung Cancer

Surabhi Dangi-Garimella, PhD

An expert panel of ASCO developed recommendations for advanced lung cancer treatment after reviewing published literature.

August 31st 2015

New 340B Draft Guidance May Increase Bureaucracy

Surabhi Dangi-Garimella, PhD

The new guidance released by HRSA proposes to improve oversight over the drug pricing program.

August 30th 2015

Pharmacy Cost Trends Expected to Continue in the Double Digits

Pharmacy cost trends are expected to increase 10% up from 6.3% the year before, with specialty pharmacy trends experiencing the largest increases, according to a survey from Aon Health.

August 28th 2015

Protein Biomarker Can Predict Response to FOLFIRINOX in Pancreatic Cancer

Surabhi Dangi-Garimella, PhD

The study published in JNCI has identified CES2 expression as a predictor of response to FOLFIRINOX.

Jennifer Malin, MD, Explains Payer Role In Changing Cancer Care

August 28th 2015

Jennifer Malin, MD, Explains Payer Role In Changing Cancer Care

While the shift to cancer becoming more of a chronic disease does not have a huge change on the approach of the payer, there are some new challenges to address, said Jennifer Malin, MD, medical director for oncology at Anthem.

August 27th 2015

Childhood Cancer Increases Risk of Recurrent Stroke

Surabhi Dangi-Garimella, PhD

Published in the journal Neurology, the study identified childhood cancer, along with hypertension and age, as a risk factor for recurrent stroke.

August 27th 2015

A New Decision Support Tool for Surgical Oncology Launched

A pathways company has followed up its medical and radiation oncology clinical decision tools with a new surgical oncology platform.

August 26th 2015

As Date for First Biosimilar to Hit the Market Draws Close, Reimbursement Remains Fuzzy

Surabhi Dangi-Garimella, PhD

The Biosimilars Council wants CMS to hold back on Medicare Part B reimbursement for biosimilars.

August 26th 2015

Do Survivorship Care Plans Improve PROs Among Cancer Patients?

Surabhi Dangi-Garimella, PhD

An article published in the Journal of Clinical Oncology finds that survivorship care plans may not greatly improve patient satisfaction with their care.

August 25th 2015

Colorectal Cancer Screening Gets Special Look in AJMC Papers

The deadly nature of colorectal cancer merited attention in the Affordable Care Act, which called for eliminating cost-sharing for screening to prevent deaths. The future of colorectal screening, its cost-effectiveness, and a possible way to limit unneeded tests are the topic of a recent series of papers in The American Journal of Managed Care.

August 25th 2015

Study Shows Promise for EHR-Based Algorithm in Reducing Cancer Diagnostic Delays

Surabhi Dangi-Garimella, PhD

A trigger built in patient EHRs can avoid follow-up delays in those at risk for developing certain types of cancers, a JCO study shows.

August 25th 2015

A Payer-Provider Collaboration to Add Value to Oncology Care

Surabhi Dangi-Garimella, PhD

Aetna and the University of Chicago Medicine kicked off a value-based oncology medical home model in July this year in an effort to transition from fee-for-service to value-based care.

August 24th 2015

Another Cancer Drug Pricing Tool, This Time From NCCN

Surabhi Dangi-Garimella, PhD

The National Comprehensive Cancer Network has announced the development of another "price" calculator that will help stakeholders assess the relative "value" of available options.

August 21st 2015

New Study Unravels Link Between Obesity and Breast Cancer

Surabhi Dangi-Garimella, PhD

The study published in Science Translational Medicine found that tissue stiffening in the breasts of obese women can drive the development of malignant disease.

Dr Veena Shankaran Encourages Patient-Physician Communication of Care Costs

August 20th 2015

Dr Veena Shankaran Encourages Patient-Physician Communication of Care Costs

There are many cost-related pieces in the grand picture of care that are devastating to families and patients, including copayments, hospital visit bills, transportation fees, and drug prices.

August 20th 2015

Phase 2 Basket Trial Results Claim Success in BRaf V600-Mutated Cancers

Surabhi Dangi-Garimella, PhD

Conducted by researchers at the Memorial Sloan Kettering Cancer Center, phase 2 results from a basket trial evaluated the efficacy of vemurafenib on nonmelanoma BRaf V600-mutated cancers in 122 patients across 23 global centers.

August 18th 2015

Pilot of Decision Support to Individualize Colorectal Cancer Screening Recommendations

Amy R. Schwartz, MD Forrest L. Levin, MS Joseph A. O'Neil, Jr, BS R. Scott Braithwaite, MD, MSc

Colorectal cancer screening involves balancing immediate harms with longer-term benefits; electronic medical record decision support may facilitate personalized benefit/harm assessment.

August 16th 2015

The Evolving Treatment Landscape and Innovative Payment Models in Oncology: An Expert Summit

This supplement summarizes proceedings from the AJMC Oncology Stakeholders Summit, Spring 2015 series, at which experts gathered to discuss the evolving treatment landscape in oncology and the development of innovative payment models to help reduce the cost of care without sacrificing quality of care.

August 16th 2015

Special Issue Looks at What's Ahead in Precision Medicine

New resources are being directed toward precision medicine, particularly in cancer care. With that in mind, Evidence-Based Oncology, a publication of The American Journal of Managed Care, devotes its current issue to articles and commentaries on this growing field.

August 14th 2015

Chemoprevention With Oral Contraceptives Could Be a Reality

Surabhi Dangi-Garimella, PhD

Evidence provided by a study published in The Lancet Oncology affirms that oral contraceptives provide long-term protection against endometrial cancer.

August 14th 2015

Gefitinib Approved as Frontline in EGFR-Positive NSCLC

Surabhi Dangi-Garimella, PhD

August 14th 2015

Need for Palliative Care for Improved Performance at the End of Life

Surabhi Dangi-Garimella, PhD

An article published in JAMA Oncology underscores the need for efforts to improve quality of life for cancer patients.

August 14th 2015

CHAARTED Study: Conceptual Shift in Early Prostate Cancer Treatment

Surabhi Dangi-Garimella, PhD

Analysis of results from the CHAARTED trial, published in the New England Journal of Medicine, has found that 6 cycles of chemotherapy (docetaxel) before androgen-deprivation therapy early in the treatment of metastatic prostate cancer significantly improved overall survival than treatment with ADT alone.

August 14th 2015

Sonidegib Approved for Basal Cell Carcinoma

Surabhi Dangi-Garimella, PhD

August 14th 2015

JAMA Oncology Study Validates Patient-Reported Outcomes

Surabhi Dangi-Garimella, PhD

A multicollaborative study conducted for the National Cancer Institute has resulted in a tool called the Common Terminology Criteria for Adverse Events (PRO-CTCAE). PRO-CTCAE can help integrate the patient perspective into adverse event reporting.

August 13th 2015

The Diagnosis for Diagnostics: Changes to Medicare Payment and Coverage of Clinical Laboratory Tests

Adam Borden, MHA Danielle Showalter, MPH Geoffrey Storchan, PhD Kathleen Hughes, MBA

The basis for determining Medicare payment rates for clinical diagnostic laboratory tests is changing. These changes will be important for all payers and providers to follow for future reimbursement and contract negotiations.

August 13th 2015

No Solution in Sight Yet With the Federal 340B Program, Say Stakeholders

Surabhi Dangi-Garimella, PhD

A panel of healthcare experts invited by The American Journal of Managed Care participated in the Oncology Stakeholders Summit, Spring 2015 Peer Exchange, to discuss 340B and other issues in oncology care.

August 13th 2015

Choosing Well in Older Breast Cancer Patients: Retrospective Study Provides Leads

Surabhi Dangi-Garimella, PhD

A study published in the Journal of the American Geriatrics Society found that older women with breast cancer have a poor response to chemotherapy, while older patients with advanced colon cancer (both men and women) did well.

August 12th 2015

The Need to Eliminate Barriers to Personalized Medicine

Alan Balch, PhD

Precision medicine will perhaps establish some of the most important biomedical innovations of our generation. However, for that future to become a reality, we have to create an access and reimbursement environment that is conducive to precision care.

...

123 124 125 126 127 128 129 130 131

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions